glutathione injections and parkinson& 39 The system in Parkinson's disease its progression Parkinson's Disease Treatment | IV

Michalski JC, Klein A

[DOI] [PMC free article] [PubMed] [Google Scholar] 172.Kamphorst BE, Stoll D, Gressner AM, Weiskirchen R

It works by blocking tyrosinase activity, effectively stopping new melanin from forming while gradually fading existing pigmentation

469 Research suggests that CRS-related toxicity may primarily involve a macrophage-centric pathophysiological mechanism, characterized by the initial activation of macrophages through CD40L-CD40 interactions within the tumor microenvironment of CAR-T cells, the release of key cytokines (such as IL-6, IL-1, and IFN-) during CRS, and the involvement of catecholamine self-amplification loops in macrophages